123 lines
70 KiB
Text
123 lines
70 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK65741">
|
|
<meta name="ncbi_domain" content="pdqcis">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK65741/?report=reader">
|
|
<meta name="ncbi_pagename" content="Hairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Hairy Cell Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]">
|
|
<meta name="citation_title" content="Hairy Cell Leukemia Treatment (PDQ®)">
|
|
<meta name="citation_publisher" content="National Cancer Institute (US)">
|
|
<meta name="citation_date" content="2024/09/20">
|
|
<meta name="citation_author" content="PDQ Adult Treatment Editorial Board">
|
|
<meta name="citation_pmid" content="26389184">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK65741/">
|
|
<meta name="citation_keywords" content="hairy cell leukemia">
|
|
<meta name="citation_keywords" content="hairy cell leukemia">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Hairy Cell Leukemia Treatment (PDQ®)">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Cancer Institute (US)">
|
|
<meta name="DC.Contributor" content="PDQ Adult Treatment Editorial Board">
|
|
<meta name="DC.Date" content="2024/09/20">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK65741/">
|
|
<meta name="description" content="Hairy cell leukemia treatment options include surveillance, chemotherapy, targeted therapy/immunotherapy, and splenectomy. The decision to treat is based on cytopenias, splenomegaly, or infectious complications. Get detailed information about hairy cell leukemia in this clinician summary.">
|
|
<meta name="og:title" content="Hairy Cell Leukemia Treatment (PDQ®)">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Hairy cell leukemia treatment options include surveillance, chemotherapy, targeted therapy/immunotherapy, and splenectomy. The decision to treat is based on cytopenias, splenomegaly, or infectious complications. Get detailed information about hairy cell leukemia in this clinician summary.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK65741/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000062926/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK65741/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8EFE007C95AAA10000000000FA00B5.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK65741/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"></div><div class="body"><div class="t">Hairy Cell Leukemia Treatment (PDQ®): Health Professional Version</div><div class="j">PDQ Cancer Information Summaries [Internet]</div></div><div class="tail"></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK65741/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK65741/&text=Hairy%20Cell%20Leukemia%20Treatment%20(PDQ%AE)"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/pdqcis/?report=reader">Title Information</a><a href="/books/n/pdqcis/toc/?report=reader">Table of Contents Page</a><a href="#_NBK65741_">Hairy Cell Leukemia Treatment (PDQ®): Health Professional Version</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK65741/?report=classic">Switch to classic view</a><a href="/books/NBK65741/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK65741%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8EFE007C95AAA10000000000FA00B5.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK65741_"><span class="title" itemprop="name">Hairy Cell Leukemia Treatment (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contribs">PDQ Adult Treatment Editorial Board.</p><p class="fm-aai"><a href="#_NBK65741_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000062926__110">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of hairy cell leukemia. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000062926__111">This summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000062926__1"><h2 id="_CDR0000062926__1_">General Information About Hairy Cell Leukemia</h2><div id="CDR0000062926__215"><h3>Incidence and Mortality</h3><p id="CDR0000062926__216">Hairy cell leukemia is an indolent, low-grade, B-cell lymphoid malignancy. It is rare, with only 1,200 to 1,300 new cases annually in the United States.[<a class="bibr" href="#CDR0000062926_rl_1_1" rid="CDR0000062926_rl_1_1">1</a>]</p></div><div id="CDR0000062926__105"><h3>Clinical Presentation</h3><p id="CDR0000062926__99">Hairy cell leukemia usually presents with:</p><ul id="CDR0000062926__100"><li class="half_rhythm"><div>Splenomegaly.</div></li><li class="half_rhythm"><div>Varying degrees
|
|
of leukopenia (occasionally leukocytosis).</div></li><li class="half_rhythm"><div>Pancytopenia.</div></li><li class="half_rhythm"><div>Monocytopenia.</div></li><li class="half_rhythm"><div> Bone marrow
|
|
infiltration by atypical cells with prominent cytoplasmic projections (i.e., hairy
|
|
cells).</div></li></ul><p id="CDR0000062926__229">Lymphadenopathy is absent, except with multiply recurrent progressive disease. </p></div><div id="CDR0000062926__106"><h3>Diagnostic Evaluation</h3><p id="CDR0000062926__219">The following tests and procedures may be used to diagnose hairy cell leukemia:</p><ul id="CDR0000062926__220"><li class="half_rhythm"><div>Flow cytometry.</div></li><li class="half_rhythm"><div>Bone marrow aspiration and biopsy.</div></li><li class="half_rhythm"><div>Immunophenotyping.</div></li><li class="half_rhythm"><div>Cytogenetic analysis.</div></li><li class="half_rhythm"><div><i>BRAF</i> gene testing.</div></li><li class="half_rhythm"><div>Computed tomography scan.</div></li></ul><p id="CDR0000062926__222"> The bone marrow is usually fibrotic and is not easily aspirated. It has circulating B cells with cytoplasmic projections (hairy appearance). Although a bone marrow biopsy may be required to enroll in a clinical trial, the hairy cell leukemia diagnosis can usually be made by flow cytometry.</p><p id="CDR0000062926__104">In addition to the B-cell antigens CD19, CD20 (very high levels), and CD22, the cells coexpress CD11c, CD25, and CD103. The <i>BRAF</i> V600E mutation is a hairy cell leukemia–defining genetic feature that can be used diagnostically.[<a class="bibr" href="#CDR0000062926_rl_1_2" rid="CDR0000062926_rl_1_2">2</a>,<a class="bibr" href="#CDR0000062926_rl_1_3" rid="CDR0000062926_rl_1_3">3</a>] A hairy cell leukemia variant (which accounts for 10% of hairy cell leukemia patients) is distinguished clinically by an elevated white blood cell count (15–50 × 10<sup>9</sup>/L) and aberrant markers, including variable (instead of bright) CD103 and the absence of CD23, CD25, CD12, and CD43.[<a class="bibr" href="#CDR0000062926_rl_1_4" rid="CDR0000062926_rl_1_4">4</a>,<a class="bibr" href="#CDR0000062926_rl_1_5" rid="CDR0000062926_rl_1_5">5</a>] Hairy cell leukemia variant cells also lack <i>BRAF</i> mutations. Patients with this variant have a more aggressive clinical course, reduced disease response to purine nucleoside analogue-based therapy, and shorter durations of response.[<a class="bibr" href="#CDR0000062926_rl_1_5" rid="CDR0000062926_rl_1_5">5</a>]</p><p id="CDR0000062926__309">The depth of a complete remission can be evaluated with measurable residual disease (MRD) by using the mutant <i>BRAF</i> gene or immunoglobulin heavy chain gene rearrangement. However, the usefulness of MRD to alter therapeutic choices remains unclear and requires further evaluation.[<a class="bibr" href="#CDR0000062926_rl_1_6" rid="CDR0000062926_rl_1_6">6</a>]</p></div><div id="CDR0000062926_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062926_rl_1_1">Troussard X, Maître E, Cornet E: Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. Am J Hematol 97 (2): 226-236, 2022. [<a href="https://pubmed.ncbi.nlm.nih.gov/34710243" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34710243</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_1_2">Tiacci E, Schiavoni G, Forconi F, et al.: Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 119 (1): 192-5, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22028477" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22028477</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_1_3">Naik RR, Saven A: My treatment approach to hairy cell leukemia. Mayo Clin Proc 87 (1): 67-76, 2012. [<a href="/pmc/articles/PMC3498175/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3498175</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22212971" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22212971</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_1_4">Jones G, Parry-Jones N, Wilkins B, et al.: Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant*. Br J Haematol 156 (2): 186-95, 2012. [<a href="https://pubmed.ncbi.nlm.nih.gov/22111844" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22111844</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_1_5">Troussard X, Grever MR: The revised guidelines for the diagnosis and management of hairy cell leukaemia and the hairy cell leukaemia variant. Br J Haematol 193 (1): 11-14, 2021. [<a href="https://pubmed.ncbi.nlm.nih.gov/33368172" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33368172</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_1_6">Ravandi F, Kreitman RJ, Tiacci E, et al.: Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J 12 (12): 165, 2022. [<a href="/pmc/articles/PMC9744664/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9744664</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36509740" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36509740</span></a>]</div></li></ol></div></div><div id="CDR0000062926__3"><h2 id="_CDR0000062926__3_">Stage Information for Hairy Cell Leukemia</h2><p id="CDR0000062926__4">There is no generally accepted staging system used in the prognosis
|
|
and treatment of hairy cell leukemia.
|
|
</p></div><div id="CDR0000062926__13"><h2 id="_CDR0000062926__13_">Treatment of Hairy Cell Leukemia</h2><p id="CDR0000062926__15">Hairy cell leukemia is highly treatable but rarely cured. Because it is easily
|
|
controlled, many patients have prolonged survival with the use of sequential therapies.
|
|
The decision to treat is based on signs of disease progression, including any of the following factors:</p><ul id="CDR0000062926__247"><li class="half_rhythm"><div>Cytopenias (especially if symptomatic).</div></li><li class="half_rhythm"><div>Increasing splenomegaly.</div></li><li class="half_rhythm"><div>The
|
|
presence of other, usually infectious, complications.</div></li></ul><p id="CDR0000062926__248">If the patient is asymptomatic and if blood counts are maintained in an
|
|
acceptable range, therapy may not be needed.[<a class="bibr" href="#CDR0000062926_rl_13_1" rid="CDR0000062926_rl_13_1">1</a>] </p><div id="CDR0000062926__252"><h3>Treatment Options for Hairy Cell Leukemia</h3><p id="CDR0000062926__253">Treatment options for hairy cell leukemia include:</p><ol id="CDR0000062926__254"><li class="half_rhythm"><div>Watchful waiting, if feasible.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__256">Rituximab</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__258">BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib</a>. </div></li><li class="half_rhythm"><div><a href="#CDR0000062926__279">Cladribine with or without rituximab</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__289">Pentostatin</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__269">Ibrutinib</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__294">Re-treatment with cladribine or pentostatin</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__314">Bendamustine with rituximab</a>.</div></li><li class="half_rhythm"><div><a href="#CDR0000062926__296">Splenectomy</a>.</div></li></ol><div id="CDR0000062926__304"><h4>Impact of COVID-19 on treatment of hairy cell leukemia</h4><p id="CDR0000062926__305">Prior to the COVID-19 (SARS-CoV-2) pandemic, the standard initial therapy for patients with hairy cell leukemia was infusion of cladribine daily for 5 days, given with or without eight weekly doses of rituximab.[<a class="bibr" href="#CDR0000062926_rl_13_2" rid="CDR0000062926_rl_13_2">2</a>-<a class="bibr" href="#CDR0000062926_rl_13_4" rid="CDR0000062926_rl_13_4">4</a>] However, treatment with a purine analogue–based regimen led to significant and prolonged neutropenia and impairment of T-cell function, which were both problematic during the pandemic in fighting viral infection and establishing vaccination-induced immunity.</p><p id="CDR0000062926__306">During the COVID-19 pandemic, some options for initial standard therapy, including cladribine or pentostatin, were replaced with other options with less toxicity; however, these options elicited less-durable responses.</p><p id="CDR0000062926__307">The Hairy Cell Leukemia Foundation convened a virtual meeting of 39 experts from around the world to amend the 2017 consensus recommendations.[<a class="bibr" href="#CDR0000062926_rl_13_5" rid="CDR0000062926_rl_13_5">5</a>] The adapted treatment guidelines, published in 2021, are based primarily on anecdotal experience and expert opinion, as controlled trials for this indolent leukemia cannot be completed expeditiously given the low incidence of this disease.[<a class="bibr" href="#CDR0000062926_rl_13_6" rid="CDR0000062926_rl_13_6">6</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] The adapted treatment guidelines are summarized below.</p><ol id="CDR0000062926__308"><li class="half_rhythm"><div>Consider watchful waiting when feasible; asymptomatic patients with noncritical levels of pancytopenia can be monitored closely.</div></li><li class="half_rhythm"><div>Avoid using cladribine, with or without rituximab,[<a class="bibr" href="#CDR0000062926_rl_13_4" rid="CDR0000062926_rl_13_4">4</a>] and pentostatin because of the risk of serious and prolonged immunosuppression.</div></li><li class="half_rhythm"><div>Consider using BRAF inhibitors such as vemurafenib, dabrafenib, or encorafenib.[<a class="bibr" href="#CDR0000062926_rl_13_7" rid="CDR0000062926_rl_13_7">7</a>-<a class="bibr" href="#CDR0000062926_rl_13_10" rid="CDR0000062926_rl_13_10">10</a>] Most patients with hairy cell leukemia are <i>BRAF</i> mutation–positive, but this status should be verified by flow cytometry. Despite extensive experience with vemurafenib for patients with relapsed disease, the U.S. Food and Drug Administration (FDA) has not approved oral vemurafenib for patients with hairy cell leukemia.</div></li><li class="half_rhythm"><div>Consider using rituximab alone intravenously (IV) for 4 to 8 weeks or in combination with a BRAF inhibitor.[<a class="bibr" href="#CDR0000062926_rl_13_11" rid="CDR0000062926_rl_13_11">11</a>] Anti-CD20 monoclonal antibodies can impair future vaccine response, but they do not affect immunity from prior vaccination.</div></li><li class="half_rhythm"><div>Interferon alfa is no longer available because production has been halted.[<a class="bibr" href="#CDR0000062926_rl_13_12" rid="CDR0000062926_rl_13_12">12</a>] According to the Hairy Cell Leukemia Foundation, ropeginterferon alfa-2b-njft is the best available preparation, but is not FDA approved for hairy cell leukemia.</div></li><li class="half_rhythm"><div>In patients with relapsed disease, the previously mentioned options are available, along with ibrutinib (the Bruton tyrosine kinase inhibitor).[<a class="bibr" href="#CDR0000062926_rl_13_13" rid="CDR0000062926_rl_13_13">13</a>] </div></li></ol></div><div id="CDR0000062926__256"><h4>Rituximab</h4><p id="CDR0000062926__257">Rituximab can induce durable remissions (with minimal toxic effects), but rarely complete remissions, in patients with multiple relapses or refractory disease after treatment with a purine analogue or interferon.[<a class="bibr" href="#CDR0000062926_rl_13_11" rid="CDR0000062926_rl_13_11">11</a>,<a class="bibr" href="#CDR0000062926_rl_13_14" rid="CDR0000062926_rl_13_14">14</a>,<a class="bibr" href="#CDR0000062926_rl_13_15" rid="CDR0000062926_rl_13_15">15</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] </p></div><div id="CDR0000062926__258"><h4>BRAF inhibitors (vemurafenib or dabrafenib) with or without rituximab or trametinib</h4><p id="CDR0000062926__259">The <i>BRAF</i> V600E mutation occurs in almost 100% of patients with classic-form hairy cell leukemia and almost never in patients with other B-cell lymphomas and leukemias, including hairy cell leukemia variants.[<a class="bibr" href="#CDR0000062926_rl_13_16" rid="CDR0000062926_rl_13_16">16</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] Vemurafenib or other BRAF inhibitors such as dabrafenib can be given with rituximab.[<a class="bibr" href="#CDR0000062926_rl_13_10" rid="CDR0000062926_rl_13_10">10</a>] The FDA has not approved BRAF inhibitors for hairy cell leukemia, but they can be used off-label in clinical practice.[<a class="bibr" href="#CDR0000062926_rl_13_15" rid="CDR0000062926_rl_13_15">15</a>]</p><p id="CDR0000062926__260">Evidence (vemurafenib with or without rituximab):</p><ol id="CDR0000062926__261"><li class="half_rhythm"><div>Several multicenter studies evaluated vemurafenib, given orally alone for 4 months or orally for 2 months with rituximab infused in eight doses over 18 weeks, in patients with relapsed or refractory hairy cell leukemia.[<a class="bibr" href="#CDR0000062926_rl_13_7" rid="CDR0000062926_rl_13_7">7</a>,<a class="bibr" href="#CDR0000062926_rl_13_8" rid="CDR0000062926_rl_13_8">8</a>,<a class="bibr" href="#CDR0000062926_rl_13_10" rid="CDR0000062926_rl_13_10">10</a>,<a class="bibr" href="#CDR0000062926_rl_13_17" rid="CDR0000062926_rl_13_17">17</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]<ol id="CDR0000062926__262" class="lower-alpha"><li class="half_rhythm"><div>After a median follow-up of 23 to 40 months, for the 86 patients treated with vemurafenib alone, the following was reported in two studies:[<a class="bibr" href="#CDR0000062926_rl_13_7" rid="CDR0000062926_rl_13_7">7</a>,<a class="bibr" href="#CDR0000062926_rl_13_8" rid="CDR0000062926_rl_13_8">8</a>,<a class="bibr" href="#CDR0000062926_rl_13_17" rid="CDR0000062926_rl_13_17">17</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]<ul id="CDR0000062926__263"><li class="half_rhythm"><div>The overall response rate was 86% to 98%.</div></li><li class="half_rhythm"><div>The complete response rate was 33% to 38%.</div></li><li class="half_rhythm"><div>The median treatment-free survival was 18 to 25 months.</div></li><li class="half_rhythm"><div>Re-treatment at relapse resulted in an 86% response rate, and the median relapse-free survival was 12.7 months in one of the trials with a 40-month median follow-up.[<a class="bibr" href="#CDR0000062926_rl_13_17" rid="CDR0000062926_rl_13_17">17</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810037/" class="def">Level of evidence C2</a>]</div></li></ul></div></li><li class="half_rhythm"><div>After a median follow-up of 37 months, for the 30 patients treated with vemurafenib plus rituximab, the following was reported:[<a class="bibr" href="#CDR0000062926_rl_13_10" rid="CDR0000062926_rl_13_10">10</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]<ul id="CDR0000062926__264"><li class="half_rhythm"><div>The complete response rate was 87%. </div></li><li class="half_rhythm"><div>The progression-free survival (PFS) rate was 78% at 37 months.</div></li><li class="half_rhythm"><div>In patients who had a complete response, 65% had no measurable residual disease (MRD).</div></li></ul></div></li></ol></div></li></ol><p id="CDR0000062926__310">Evidence (dabrafenib plus trametinib):</p><ol id="CDR0000062926__311"><li class="half_rhythm"><div>In a phase II trial of patients with relapsed or refractory disease, 55 patients received dabrafenib and trametinib orally until disease progression, unacceptable toxicity, or death.[<a class="bibr" href="#CDR0000062926_rl_13_18" rid="CDR0000062926_rl_13_18">18</a>]<ul id="CDR0000062926__312"><li class="half_rhythm"><div>With a median follow-up of 43.2 months, the overall response rate was 89.0% (95% confidence interval [CI], 77.8%–95.9%), the complete response rate was 65.5%, the 2-year PFS rate was 94.5%, and the 2-year overall survival (OS) rate was 95.5%.[<a class="bibr" href="#CDR0000062926_rl_13_18" rid="CDR0000062926_rl_13_18">18</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810035/" class="def">Level of evidence C1</a>]</div></li></ul></div></li></ol></div><div id="CDR0000062926__279"><h4>Cladribine with or without rituximab</h4><p id="CDR0000062926__280">Cladribine may be given with or without rituximab to treat hairy cell leukemia.</p><p id="CDR0000062926__281">Evidence (cladribine with or without rituximab):</p><ol id="CDR0000062926__282"><li class="half_rhythm"><div>In a phase II study, 68 patients with previously untreated hairy cell leukemia were randomly assigned to receive cladribine (0.15 mg/kg IV) on days 1 to 5, with eight weekly doses of rituximab either concurrently (starting on day 1) or delayed (starting after 6 months of cladribine treatment) if still positive with MRD testing.[<a class="bibr" href="#CDR0000062926_rl_13_4" rid="CDR0000062926_rl_13_4">4</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]<ul id="CDR0000062926__313"><li class="half_rhythm"><div>With a median follow-up of 96 months, 94% of patients who received concurrent therapy were MRD-free, compared with 12% of patients who received delayed therapy.</div></li><li class="half_rhythm"><div>Although patients who underwent concurrent therapy had more need for platelet transfusions, they demonstrated higher neutrophil and platelet counts after 1 month.</div></li><li class="half_rhythm"><div>A retrospective case series reported a median PFS of 67 months in patients with relapsed disease who received a purine nucleoside analogue (usually cladribine) plus rituximab.[<a class="bibr" href="#CDR0000062926_rl_13_19" rid="CDR0000062926_rl_13_19">19</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810037/" class="def">Level of evidence C2</a>]</div></li><li class="half_rhythm"><div>A retrospective case series of nine patients with a hairy cell leukemia variant histology reported an 88% complete response rate and 3-year PFS rate of 42% (95% CI, 1%–84%) after treatment with a purine nucleoside analogue (usually cladribine) plus rituximab.[<a class="bibr" href="#CDR0000062926_rl_13_20" rid="CDR0000062926_rl_13_20">20</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810037/" class="def">Level of evidence C2</a>]</div></li></ul></div></li><li class="half_rhythm"><div>Cladribine was given by daily subcutaneous injections or by daily 2-hour IV infusions for 5 to 7 days.[<a class="bibr" href="#CDR0000062926_rl_13_5" rid="CDR0000062926_rl_13_5">5</a>,<a class="bibr" href="#CDR0000062926_rl_13_21" rid="CDR0000062926_rl_13_21">21</a>-<a class="bibr" href="#CDR0000062926_rl_13_23" rid="CDR0000062926_rl_13_23">23</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]
|
|
Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.<ul id="CDR0000062926__283"><li class="half_rhythm"><div>The complete response rate was 50% to 80%.</div></li><li class="half_rhythm"><div>The overall response rate was 85% to 95%.</div></li></ul></div></li><li class="half_rhythm"><div>A National Cancer Institute group C protocol of 979 patients treated with cladribine reported lower response rates (i.e., 50% complete remission rate, 37% partial
|
|
remission rate) compared with other studies.[<a class="bibr" href="#CDR0000062926_rl_13_24" rid="CDR0000062926_rl_13_24">24</a>] Responses were durable in patients treated with a short course of cladribine,
|
|
and patients who had a relapse often responded to re-treatment with cladribine.[<a class="bibr" href="#CDR0000062926_rl_13_2" rid="CDR0000062926_rl_13_2">2</a>,<a class="bibr" href="#CDR0000062926_rl_13_19" rid="CDR0000062926_rl_13_19">19</a>,<a class="bibr" href="#CDR0000062926_rl_13_25" rid="CDR0000062926_rl_13_25">25</a>]</div></li><li class="half_rhythm"><div>A retrospective review included 83 patients, aged 40 years and younger.[<a class="bibr" href="#CDR0000062926_rl_13_2" rid="CDR0000062926_rl_13_2">2</a>]<ul id="CDR0000062926__284"><li class="half_rhythm"><div>The median time to first relapse was 54 months for all responders, and the median OS was 21 years from diagnosis.</div></li><li class="half_rhythm"><div>Cladribine may cause fever and immunosuppression; documented infection was found in 33% of treated patients. </div></li></ul></div></li></ol><p id="CDR0000062926__287">In a retrospective study of patients with
|
|
cladribine-associated neutropenic fever, filgrastim (G-CSF) did not reduce the percentage of febrile patients, number of febrile days, or
|
|
frequency of hospital admissions to receive antibiotics.[<a class="bibr" href="#CDR0000062926_rl_13_3" rid="CDR0000062926_rl_13_3">3</a>]</p></div><div id="CDR0000062926__289"><h4>Pentostatin</h4><p id="CDR0000062926__290">Pentostatin given IV every other week for 3 to 6 months produced
|
|
a 50% to 76% complete response rate and an 80% to 87% overall response
|
|
rate.[<a class="bibr" href="#CDR0000062926_rl_13_26" rid="CDR0000062926_rl_13_26">26</a>] Complete remissions were of substantial duration. Purine analogues should be avoided in cases of active infection or moderate to severe hepatic or renal impairment.</p><p id="CDR0000062926__291">Evidence (pentostatin):</p><ol id="CDR0000062926__292"><li class="half_rhythm"><div>Two trials
|
|
reported results on the 9-year median follow-up of patients treated with pentostatin.[<a class="bibr" href="#CDR0000062926_rl_13_27" rid="CDR0000062926_rl_13_27">27</a>,<a class="bibr" href="#CDR0000062926_rl_13_28" rid="CDR0000062926_rl_13_28">28</a>]<ul id="CDR0000062926__293"><li class="half_rhythm"><div>The relapse-free survival rates ranged from 56% to
|
|
67%.</div></li><li class="half_rhythm"><div>Side effects included fever, immunosuppression, cytopenias, and
|
|
renal dysfunction. </div></li></ul></div></li><li class="half_rhythm"><div> A randomized trial compared pentostatin to recombinant interferon alfa-2a.[<a class="bibr" href="#CDR0000062926_rl_13_26" rid="CDR0000062926_rl_13_26">26</a>]<ul id="CDR0000062926__303"><li class="half_rhythm"><div>Pentostatin demonstrated higher response rates and more durable responses.</div></li></ul></div></li></ol></div><div id="CDR0000062926__269"><h4>Ibrutinib</h4><p id="CDR0000062926__270">Ibrutinib, a tyrosine kinase inhibitor, has been studied in the treatment of hairy cell leukemia.</p><p id="CDR0000062926__271">Evidence (ibrutinib):</p><ol id="CDR0000062926__272"><li class="half_rhythm"><div>In a phase II study, 37 patients with refractory hairy cell leukemia were treated with ibrutinib. The median follow-up was 42 months.[<a class="bibr" href="#CDR0000062926_rl_13_29" rid="CDR0000062926_rl_13_29">29</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] <ul id="CDR0000062926__273"><li class="half_rhythm"><div>The response rate was 54%.</div></li><li class="half_rhythm"><div>The estimated 36-month PFS rate was 73%.</div></li><li class="half_rhythm"><div>The OS rate was 85%.</div></li></ul></div></li></ol></div><div id="CDR0000062926__294"><h4>Re-treatment with cladribine or pentostatin</h4><p id="CDR0000062926__295">Patients with hairy cell leukemia who have a relapse after the first course of cladribine or pentostatin often respond
|
|
well to re-treatment with the same or another purine analogue, especially if relapse occurs after several years.[<a class="bibr" href="#CDR0000062926_rl_13_19" rid="CDR0000062926_rl_13_19">19</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>]</p></div><div id="CDR0000062926__314"><h4>Bendamustine with rituximab</h4><p id="CDR0000062926__315">Evidence (bendamustine with rituximab):</p><ol id="CDR0000062926__316"><li class="half_rhythm"><div>A phase II study evaluated 12 patients with relapsed or refractory disease, three of whom were negative for a <i>BRAF</i> mutation. Patients received the combination of bendamustine and rituximab.[<a class="bibr" href="#CDR0000062926_rl_13_30" rid="CDR0000062926_rl_13_30">30</a>]<ul id="CDR0000062926__317"><li class="half_rhythm"><div>The overall response rate was 100%, and the complete remission rate was 50%.[<a class="bibr" href="#CDR0000062926_rl_13_30" rid="CDR0000062926_rl_13_30">30</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000810039/" class="def">Level of evidence C3</a>] </div></li></ul></div></li></ol></div><div id="CDR0000062926__296"><h4>Splenectomy</h4><p id="CDR0000062926__297">Splenectomy plays a
|
|
decreasing role in treating hairy cell leukemia because effective alternatives are available. Splenectomy will partially or completely normalize the peripheral blood in
|
|
most patients with hairy cell leukemia.[<a class="bibr" href="#CDR0000062926_rl_13_31" rid="CDR0000062926_rl_13_31">31</a>] After a splenectomy, there is usually
|
|
little or no change in the bone marrow, and virtually all
|
|
patients have progressive disease within 12 to 18 months.
|
|
</p></div></div><div id="CDR0000062926__TrialSearch_13_sid_3"><h3>Current Clinical Trials</h3><p id="CDR0000062926__TrialSearch_13_22">Use our <a href="https://www.cancer.gov/research/participate/clinical-trials-search/advanced" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/research/participate/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">General information</a> about clinical trials is also available.</p></div><div id="CDR0000062926_rl_13"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062926_rl_13_1">Troussard X, Maître E, Cornet E: Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment. Am J Hematol 97 (2): 226-236, 2022. [<a href="https://pubmed.ncbi.nlm.nih.gov/34710243" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34710243</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_2">Rosenberg JD, Burian C, Waalen J, et al.: Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood 123 (2): 177-83, 2014. [<a href="https://pubmed.ncbi.nlm.nih.gov/24192579" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24192579</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_3">Saven A, Burian C, Adusumalli J, et al.: Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood 93 (8): 2471-7, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10194424" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10194424</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_4">Chihara D, Arons E, Stetler-Stevenson M, et al.: Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia. J Clin Oncol 38 (14): 1527-1538, 2020. [<a href="/pmc/articles/PMC7213585/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7213585</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32109194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32109194</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_5">Grever MR, Abdel-Wahab O, Andritsos LA, et al.: Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129 (5): 553-560, 2017. [<a href="/pmc/articles/PMC5290982/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5290982</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27903528" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27903528</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_6">Grever M, Andritsos L, Banerji V, et al.: Hairy cell leukemia and COVID-19 adaptation of treatment guidelines. Leukemia 35 (7): 1864-1872, 2021. [<a href="/pmc/articles/PMC8093591/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8093591</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33947938" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33947938</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_7">Tiacci E, Park JH, De Carolis L, et al.: Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. N Engl J Med 373 (18): 1733-47, 2015. [<a href="/pmc/articles/PMC4811324/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4811324</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26352686" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26352686</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_8">Dietrich S, Pircher A, Endris V, et al.: BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 127 (23): 2847-55, 2016. [<a href="https://pubmed.ncbi.nlm.nih.gov/26941398" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26941398</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_9">Falini B, Tiacci E: New treatment options in hairy cell leukemia with focus on BRAF inhibitors. Hematol Oncol 37 (Suppl 1): 30-37, 2019. [<a href="https://pubmed.ncbi.nlm.nih.gov/31187521" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31187521</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_10">Tiacci E, De Carolis L, Simonetti E, et al.: Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia. N Engl J Med 384 (19): 1810-1823, 2021. [<a href="https://pubmed.ncbi.nlm.nih.gov/33979489" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33979489</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_11">Angelopoulou MK, Pangalis GA, Sachanas S, et al.: Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma 49 (9): 1817-20, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18798112" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18798112</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_12">Assanto GM, Riemma C, Malaspina F, et al.: The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. Br J Haematol 194 (1): 78-82, 2021. [<a href="/pmc/articles/PMC8360059/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8360059</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33932027" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33932027</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_13">Jones J, Andritsos L, Kreitman RJ: Efficacy and safety of the Bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1 results of a phase 2 study. [Abstract] Blood 128 (22): A-1215, 2016.</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_14">Thomas DA, O'Brien S, Bueso-Ramos C, et al.: Rituximab in relapsed or refractory hairy cell leukemia. Blood 102 (12): 3906-11, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12816862" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12816862</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_15">Falini B, De Carolis L, Tiacci E: How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors. Blood 139 (15): 2294-2305, 2022. [<a href="/pmc/articles/PMC11022828/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC11022828</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35143639" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35143639</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_16">Pettirossi V, Santi A, Imperi E, et al.: BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood 125 (8): 1207-16, 2015. [<a href="/pmc/articles/PMC4366655/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4366655</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25480661" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25480661</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_17">Handa S, Lee JO, Derkach A, et al.: Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood 140 (25): 2663-2671, 2022. [<a href="/pmc/articles/PMC9935554/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9935554</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35930750" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35930750</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_18">Kreitman RJ, Moreau P, Ravandi F, et al.: Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia. Blood 141 (9): 996-1006, 2023. [<a href="/pmc/articles/PMC10163281/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC10163281</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36108341" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 36108341</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_19">Hu R, Wei W, Mian A, et al.: Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse. Eur J Haematol 108 (5): 379-382, 2022. [<a href="https://pubmed.ncbi.nlm.nih.gov/35043475" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35043475</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_20">Wang Y, Wang T, Yu Y, et al.: Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant. Ann Hematol 101 (6): 1201-1210, 2022. [<a href="https://pubmed.ncbi.nlm.nih.gov/35437610" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35437610</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_21">Pagano L, Criscuolo M, Broccoli A, et al.: Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study. Blood Cancer J 12 (7): 109, 2022. [<a href="/pmc/articles/PMC9296486/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9296486</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35853850" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35853850</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_22">Zenhäusern R, Schmitz SF, Solenthaler M, et al.: Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). Leuk Lymphoma 50 (9): 1501-11, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19672771" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19672771</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_23">Hermel DJ, Cheng B, Bhangoo MS, et al.: Long-term outcomes of elderly hairy cell leukemia patients treated with cladribine. Ann Hematol 101 (5): 1089-1096, 2022. [<a href="https://pubmed.ncbi.nlm.nih.gov/35218397" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35218397</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_24">Cheson BD, Sorensen JM, Vena DA, et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 16 (9): 3007-15, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9738569" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9738569</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_25">Else M, Dearden CE, Catovsky D: Long-term follow-up after purine analogue therapy in hairy cell leukaemia. Best Pract Res Clin Haematol 28 (4): 217-29, 2015. [<a href="/pmc/articles/PMC5509559/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5509559</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26614900" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26614900</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_26">Grever M, Kopecky K, Foucar MK, et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol 13 (4): 974-82, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7707126" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7707126</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_27">Johnston JB, Eisenhauer E, Wainman N, et al.: Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin Oncol 27 (2 Suppl 5): 32-6, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10877049" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10877049</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_28">Flinn IW, Kopecky KJ, Foucar MK, et al.: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 96 (9): 2981-6, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/11049974" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11049974</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_29">Rogers KA, Andritsos LA, Wei L, et al.: Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood 137 (25): 3473-3483, 2021. [<a href="/pmc/articles/PMC8225920/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8225920</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33754642" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 33754642</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_30">Burotto M, Stetler-Stevenson M, Arons E, et al.: Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res 19 (22): 6313-21, 2013. [<a href="/pmc/articles/PMC3861900/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3861900</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24097860" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24097860</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062926_rl_13_31">Golomb HM, Vardiman JW: Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood 61 (2): 349-52, 1983. [<a href="https://pubmed.ncbi.nlm.nih.gov/6821700" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6821700</span></a>]</div></li></ol></div></div><div id="CDR0000062926__32"><h2 id="_CDR0000062926__32_">Latest Updates to This Summary (09/20/2024)</h2><p id="CDR0000062926__33">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="CDR0000062926__334">Editorial changes were made to this summary.</p><p id="CDR0000062926__disclaimerHP_3">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is
|
|
editorially independent of NCI. The summary reflects an independent review of
|
|
the literature and does not represent a policy statement of NCI or NIH. More
|
|
information about summary policies and the role of the PDQ Editorial Boards in
|
|
maintaining the PDQ summaries can be found on the <a href="#CDR0000062926__AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® Cancer Information for Health Professionals</a> pages.
|
|
</p></div><div id="CDR0000062926__AboutThis_1"><h2 id="_CDR0000062926__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000062926__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000062926__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of hairy cell leukemia. It is intended as a resource to inform and assist clinicians in the care of their patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000062926__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000062926__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/adult-treatment" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Adult Treatment Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000062926__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000062926__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000062926__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p>The lead reviewer for Hairy Cell Leukemia Treatment is:</p><ul><li class="half_rhythm"><div>Eric J. Seifter, MD (Johns Hopkins University)</div></li></ul><p id="CDR0000062926__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000062926__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000062926__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <a href="/books/n/pdqcis/CDR0000062796/?report=reader">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000062926__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000062926__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000062926__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000062926__AboutThis_15">PDQ® Adult Treatment Editorial Board. PDQ Hairy Cell Leukemia Treatment. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: <a href="https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq</a>. Accessed <MM/DD/YYYY>. [PMID: 26389184]</p><p id="CDR0000062926__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
|
</p></div><div id="CDR0000062926__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000062926__AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000062926__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000062926__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div></div></div><div class="fm-sec"><h2 id="_NBK65741_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><p class="contrib-group"><h4>Authors</h4><span itemprop="author">PDQ Adult Treatment Editorial Board</span>.</p><h3>Publication History</h3><p class="small">Published online: September 20, 2024.</p><h3>Version History</h3><ul class="simple-list" style="padding:0"><li><span class="bk_col_itm">NBK65741.9</span> September 20, 2024 (Displayed Version)</li><li><span class="bk_col_itm"><a href="/books/NBK65741.8/?report=reader">NBK65741.8</a></span> February 9, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK65741.7/?report=reader">NBK65741.7</a></span> December 21, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65741.6/?report=reader">NBK65741.6</a></span> January 14, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK65741.5/?report=reader">NBK65741.5</a></span> December 17, 2020</li><li><span class="bk_col_itm"><a href="/books/NBK65741.4/?report=reader">NBK65741.4</a></span> November 25, 2020</li><li><span class="bk_col_itm"><a href="/books/NBK65741.3/?report=reader">NBK65741.3</a></span> March 23, 2018</li><li><span class="bk_col_itm"><a href="/books/NBK65741.2/?report=reader">NBK65741.2</a></span> March 18, 2016</li><li><span class="bk_col_itm"><a href="/books/NBK65741.1/?report=reader">NBK65741.1</a></span> July 8, 2015</li></ul><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>PDQ Adult Treatment Editorial Board. Hairy Cell Leukemia Treatment (PDQ®): Health Professional Version. 2024 Sep 20. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|